alexa Evaluation Of Keytruda For Metastatic Non-small Cell Lung Cancer
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Joint Event: 3rd International Conference on Biopharmaceutics and Biologic Drugs & 5th International Pharmacy Conference
August 31-September 01, 2017 Philadelphia, USA

Dewilka Simons
Temple University School of Pharmacy, USA
Posters & Accepted Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851-C1-031
Abstract
Keytruda (Pembrolizumab) is the only anti-PD-1 treatment approved for first-line combination with pemetrexed and carboplatin and/or as monotherapy for the treatment of metastatic non-small cell lung cancer (mNSCLC) in appropriate patients. Lung cancer is the second most common form of cancer in both men and women and NSCLC accounts for 80%- 85% of all lung cancers. The 5-year survival rate for metastatic lung cancer is <18.1%. Cancer immunotherapy works by enhancing or allowing the immune system to recognize and destroy cancer cells. Clinical responses targeting the programmed cell death-1 (PD-1) pathway have shown promise in improving survival while maintaining a relatively tolerable toxicity profile. Combination therapy with pemetrexed and carboplatin received accelerated approval based on tumor response rate and progression-free survival in clinical trials. In combination therapy, the use of Keytruda is irrespective of PD-L1 status. The use of Keytruda in the first-line monotherapy setting requires to have high expressions of PD-L1 with a tumor proportion score (TPS) ≥50% in which the TPS must be determined by an FDA-approved test. The monotherapy indication received approval based on overall survival and progression-free survival data in clinical trials.
Biography

Dewilka Simons is currently a third-year Pharmacy student at Temple University School of Pharmacy in Philadelphia. She has received her BS in Life Science from the Pennsylvania State University in 2014 with an emphasis in cultural studies. Her interests are transplant therapy, critical care and infectious disease in immunocompromised patients and patient education. She is the Vice President of the Interdisciplinary Health Advocacy (IDHA) a student run organization that promotes interprofessional patient outreach. She hopes to pursue PGY-1 and PGY-2 residency in solid organ transplant upon graduation.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords